Procurement procedures for viral hepatitis B vaccines will end in August, and the vaccine will be delivered to medical organizations in the country.

Asemgul Yerzhanova, managing director of "SK-Pharmaceuticals" said that tender procedures for the purchase of viral hepatitis B vaccine (VGV, recombinant) were repeatedly announced, however, low prices were virtually non-existent. Asemgul Yerzhanova explained "Taking into account the importance of procurement of vaccines, the Ministry of Healthcare's order on May 11, 2017, has increased the dose from 148.22 tenge to 420.0 tenge".

After reviewing the price of 30 May, the single distributor announced new tender using two-step procedures, recombinant vaccine for the prevention of hepatitis B, the potential supplier of the pharmaceutical company LLP "Pharmactiv", the LG Life Sciences Ltd., Republic of Korea.

 According to the Managing Director of "SK-Pharmaceuticals ", the single distributor currently completes the procurement procedure for this vaccine. Yeremzhanova added "Delivery of the vaccines to the United States distributor's warehouses starts in September, and then the drug is dispatched to medicines that need immediate attention".

The problems that have been taken in the procurement of a vaccine against viral hepatitis B have been previously considered by the Ministry of Health. Until the vaccine acquisition ends, it has been suggested to redistribute the drug to the regions where healthcare authorities already have a need for regions where vaccine reserves are available. Redistribution of vaccines was carried out in four regions.

It should be noted that annually, the single distributor will buy about 20 vaccines. Their list shall be sent to the single distributor for the purpose of purchasing by the authorized body in the field of health, specifying the maximum price.